| 前收市價 | 15.00 |
| 開市 | 15.00 |
| 買盤 | 13.65 |
| 賣出價 | 14.45 |
| 拍板 | 160.00 |
| 到期日 | 2026-01-16 |
| 今日波幅 | 15.00 - 15.00 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 334 |
ReutersJ&J-backed startup Rapport files for US IPO
Rapport, which develops small molecule medicines for patients suffering from central nervous system disorders, is gearing up for a listing as the IPO market recovers from a slump amid increasing hopes of a soft landing for the economy. The company said it will be selling shares in the IPO, but did not disclose how many nor the price range. Rapport's net loss widened to $34.8 million in 2023 from $10.7 million a year earlier.
ZacksJ&J (JNJ) to Boost Dermatology Portfolio With New Acquisition
Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.
BenzingaJohnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
Thursday, Johnson & Johnson (NYSE:JNJ) agreed to acquire Proteologix Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with the potential for an additional milestone payment. Proteologix’s portfolio includes: PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic dermatitis (AD) and moderate to severe asthma. PX130, a bispecific antibody t
